Data from a phase 1, open-label, multi-center safety trial of lyophilized platelets were recently presented at the 2019 AABB Annual Meeting in San Antonio, Texas.
About Cellphire
Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com.
Contacts:
Media
Sharon Burns
Director, Communications
sburns@cellphire.com
Investor Relations
Tom Dann
Chief Investment Officer
tdann@cellphire.com